Surgical Science Sweden (WKN: A2P46G)

Surgical Science Sweden AB ist ein in Schweden ansässiges Unternehmen, das Virtual-Reality-Simulatoren für evidenzbasiertes laparoskopisches und endoskopisches Training anbietet. Die Systeme umfassen LapSim-, EndoSim- und TeamSim-Schulungen. Jedes Training kombiniert Grafiken und kognitive Instruktionen, beinhaltet die Navigation auf Touchscreens und verfügt über taktile Feedback-Technologie. Die LapSim-Schulungen bestehen aus laparoskopischen Übungen, die von grundlegender Navigation bis zu fortgeschrittenem Nähen reichen, die endoskopischen Übungen von EndoSim reichen von Funktionen des Zielfernrohrgriffs und des Tubus bis zur Schleifenreduktion. TeamSim umfasst Prozedurmodule für das Training in einer realen Operationssaalumgebung und hilft, die Kommunikationsfähigkeiten des Teams in Krisen- und Routinesituationen aufzubauen. Die Trainingssysteme werden von medizinischen Ausbildungszentren und Instituten weltweit für die Praxis, Validierung und Zertifizierung von Studenten, Chirurgen und Ärzten eingesetzt.

Heute wieder mit guten Zahlen. Ich bin ab heute mit einer Anfangsposiition  investiert. Leider in D nur schwer handelbar. Deshalb sollte man möglichst in Stockholm kaufen.

https://www.marketscreener.com/quote/stock/...D-OF-THE-YEAR-32414586/

2/11/2021 | 07:31am GMT

FOURTH QUARTER 2020 (OCT - DEC)

Net sales amounted to SEK 39.6 million (39.3), corresponding to an increase of 1 percent compared with the corresponding period in the preceding year.

Operating profit amounted to SEK 12.6 million (12.4).

Net profit amounted to SEK 10.6 million (9.2), corresponding to earnings per share of SEK 0.31 (0.27).

Cash flow from operating activities amounted to SEK 16.7 million (7.9). As of December 31, 2020, cash and cash equivalents amounted to SEK 87.2 million (69.2).

FULL-YEAR 2020

Net sales amounted to SEK 104.8 million (101.5), corresponding to an increase of 3 percent compared with the corresponding period in the preceding year.

For comparable units, sales decreased by 19 percent.

Operating profit amounted to SEK 20.0 million (15.2).

Net profit amounted to SEK 15.6 million (12.6), corresponding to earnings per share of SEK 0.45 (0.45).

Cash flow from operating activities amounted to SEK 23.2 million (55.2).

FOLLOWING THE CLOSE OF THE YEAR

On January 20, 2021, a conditional agreement was entered into to acquire all of the shares in Mimic Technologies Inc. ("Mimic"), which operates in the area of robotic surgery. Mimic is based in Seattle in the US, and the acquisition provides Surgical Science with an additional customer base in robotic surgery, contributes data collection/analysis technology and significantly strengthens the presence in the important US market. The initial purchase consideration was USD 18 million (approximately SEK 150 million) on a cash and debt-free basis. In addition, a maximum USD 15.6 million (approximately SEK 130 million) may be paid as a deferred contingent consideration.

A private placement of approximately SEK 322 million was implemented, in which a number of new and existing Swedish and international institutional investors subscribed for shares. The transfer of ownership took place on January 27, 2021, once all of the terms of transfer had been met. Mimic will be consolidated within Surgical Science as of the transfer date.

Gothenburg, Sweden, February 11, 2021

Surgical Science Sweden AB (publ)

This report, in its entirety, is available through the attachment or via:

https://surgicalscience.com/aktien/pressmeddelanden/

https://surgicalscience.com/aktien/finansiella-rapporter/

For further information, please contact:

Gisli Hennermark, CEO

Telephone: +46 70 420 83 00

E-mail: gisli.hennermark@surgicalscience.com

Anna Ahlberg, CFO

Telephone: +46 70 855 38 35

E-mail: anna.ahlberg@surgicalscience.com